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Summary
 Aim To review literature data concerning treatment of procedure-related complica-
tions in the intensive care unit in children undergoing allogeneic haematopoi-
etic stem cell transplantation with a focus on clinical results, limitations of stud-
ies, recent improvements and remaining problems.
 Materials/Methods A review of PubMed references based on evidence-based recommendations and 
own experience.
 Results Modern ICU care both for adults and children undergoing HSCT has improved 
in the last decade. However, multi-organ system failure and those requiring me-
chanical ventilation have the worst outcome. Within the paediatric setting the 
majority of children are transferred for respiratory support and pulmonary com-
plications. Septic shock and its consequences are associated with far fewer admis-
sions to the ICU. The role of the ICU requires constant revision as protocols and 
treatments change both in the HSCT unit as well as in intensive care.
 Conclusions An adequate scoring system such as an adapted O-PRISM should be developed 
and would lead to the possibility of multi-centre comparative data acquisition 
and develop future studies in this critically ill group of patients.
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BACKGROUND
Haematopoietic stem cell transplantation (HSCT) 
can be the only curative option for some chil-
dren with a life-threatening illness. However, be 
it related to procedural toxicities or pre-existing 
conditions, some children become critically un-
well during the procedure and a proportion of 
these patients, mainly with visceral organ injury, 
systemic infection or GvHD, may beneﬁ t from 
specialized intensive care support.
Historically, the reported survival of these pa-
tients (mainly adults) has been poor [1]. Children 
have also been reported, albeit comparably less 
frequently, and may do better than their adult 
counterparts [2–10].
As such, the question of whether to admit such 
patients to the ICU remains an issue. However, 
many of the reports are now decades old and ad-
vances in intensive care medicine have mirrored 
those of HSCT. Recently these historical observa-
tions have been called into question [1].
AIM
To review literature data concerning treatment of 
procedure-related complications in the intensive 
care unit in children undergoing allogeneic hae-
matopoietic stem cell transplantation with a focus 
on clinical results, limitations of studies, recent 
improvements and remaining problems.
MATERIALS AND METHODS
References were retrieved using the online 
database of the National Library of Medicine 
(PubMed; http://www.ncbi.nlm.nih.gov/PubMed). 
Terms used included: intensive care, transplant re-
lated complications, allogeneic HSCT in children. 
The retrieved references were supplemented by 
references from the author’s own database.
RESULTS
To date, 9 single centre studies have been re-
ported, ranging from 1983 to 2001 [2–10]. A 
total of 1075 (725 allogeneic and 350 autolo-
gous) bone marrow or peripheral blood stem 
cell transplants were included. As to be expect-
ed, the most were transplanted for malignant 
disease (49%). Respiratory complications ac-
counted for approximately half of the admis-
sions (n=410), with septic shock in only 6% of 
patients. The percentage of patients admitted to 
the ICU requiring ventilation ranged from 63 to 
88% (median 84%).
Prior to 2000 rates of admission to the paediatric 
ICU ranged from 11 to 18% of HSCT patients, 
after which an increase was observed from 16 to 
29%. There are no data other than pre 2000 for 
ventilation rates (7–23%) or reported survival to 
hospital discharge in these studies.
Survival to hospital discharge in ventilated patients 
was however reported in one study and improved 
from 11% pre 2000 to 28% post 2000 [8].
Three reports have described paediatric ICU sup-
port in children undergoing umbilical cord blood 
transplantation (UCBT) [5,8,10]. Only one of 
these contained sufﬁ cient numbers of children 
for a meaningful analysis, and included 98 ICU 
admissions in a 9-year period comparing 52 UCBT 
children and 34 BMT patients [8].
Forty-one percent survived the ICU period but 
only 28% survived to hospital discharge, with an 
overall survival at 2 years of 20%. There was no 
signiﬁ cant difference in survival (ICU and hospi-
tal discharge) between BMT and UCBT patients 
even though UCBT patients required longer me-
chanical ventilation (18.2 vs 9.1 days).
Multi-organ system failure (MSOF), prolonged 
mechanical ventilation and respiratory failure 
were associated with an increased risk of mor-
tality, similar to that seen in adults [2–10]. Our 
experience in Leiden is similar in that patients 
are rarely transferred to the ICU other than for 
respiratory support and those with MSOF have a 
poor outcome. Children with neurological prob-
lems, bleeding and GI problems fare better, but 
often children have complex problems that com-
bine to make management difﬁ cult.
The oncological paediatric risk of mortality score 
(O-PRISM) has been criticized in predicting out-
come in the paediatric HSCT-ICU setting but re-
mains the best predictive score of outcome to 
date [4].
DISCUSSION
Limitations of studies
There is a great deal of variability in the patient 
population studies. Most studies in adults failed 
to calculate the percentage of patients admitted 
to the ICU as well as failing to address issues such 
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as patient selection bias. Over time the number of 
patients transferred to the ICU has diminished as 
have the mechanical ventilation rates. Almost all 
reports are single centre and comparisons can-
not easily be made among centres as the thresh-
old variables for ICU transfer and ventilation vary 
considerably among units [1].
Improvements
Certain improvements over the last decades can 
be attributed to the advances both in HSCT and 
ICU medicine. However, increased awareness of 
the “futility” of transferring some patients may 
contribute to the reports of improved survival. 
Two reports, both in adults, have concluded this 
to be the case.
Advances in HSCT which may contribute to over-
all survival and less toxicity, thus reducing trans-
fer to the ICU, can be summarized as follows:
a.  Use of new agents such as Deﬁ brotide® and im-
proved less toxic regimens such as Busulfex® 
with pharmacological monitoring has im-
proved the visceral toxicity associated with 
VOD [11,12].
b.  Blood product support such as leukocyte de-
pleted red cells and the use of granulocyte 
transfusions have reduced the risks of lethal 
infections [13]. Close monitoring of PCR vi-
ral reactivations in the post-transplant peri-
od have allowed for the timely introduction 
of anti-viral medications and reduced system-
ic infection [14].
c.  Developments in the management of steroid 
refractory GvHD such as the use of 3rd par-
ty mesenchymal stem cells have reduced the 
mortality associated with severe disease [15].
d.  Use of G-CSF in the post-transplant period to 
reduce the period of neutropenia [16].
e.  Use of reduced intensity regimens in children 
clinically unﬁ t for standard conditioning reg-
imens [17].
f.  Initial multi-disciplinary management may im-
prove patient outcome but this is as yet to be 
determined. What is important is the commu-
nication amongst haemato-oncologists, ICU 
staff and parents and child.
Progress in ICU techniques and knowledge has 
paralleled those of HSCT such as:
a.  Lung protective strategies – lower tidal vol-
ume during mechanical ventilation.
b.  Non-invasive positive pressure ventilation.
c.  Early goal directed therapy in patients with septic 
shock (only in adults and not yet in HSCT).
Increasing risks
Increasing risk to patients undergoing HSCT in-
dicates that assessment of the role of ICU sup-
port is a dynamic process and can be summa-
rized as follows:
a.  The increasing use of immune therapy such 
as DLIs with the increased risk of GvHD as a 
complication of treatment [18].
b.  The expansion of donor stem cell sources in-
clusive of haploidentical and mismatch cord 
blood transplants with delayed immune and/or 
haematopoietic reconstitution leading to more 
infective complications.
c.  Changing patient and donor selection crite-
ria with less identical HSCT being undertak-
en compared to unrelated matched or mis-
matched transplants.
CONCLUSIONS
Modern ICU care both for adults and children 
undergoing HSCT has improved in the last dec-
ade. However, multi-organ system failure and 
those requiring mechanical ventilation have the 
worst outcome. Within the paediatric setting 
the majority of children are transferred for res-
piratory support and pulmonary complications. 
Septic shock and its consequences are associated 
with far fewer admissions to the ICU. The role of 
the ICU requires constant revision as protocols 
and treatments change both in the HSCT unit 
as well as in intensive care. An adequate scoring 
system such as an adapted O-PRISM should be 
developed and would lead to the possibility of 
multi-centre comparative data acquisition and 
develop future studies in this critically ill group 
of patients.
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